Zyprexa

Sales next year are expected to increase 7-9 per cent to more than $15bn (€12.6 billion).

Barriers to this growth are tough US trends in its important markets of antipsychotics and antidepressants.

E-mail this page to a colleague Print in friendly format Copyright - Unless otherwise stated all contents of this web site are © 2000/2005 – Decision News Media SAS – All Rights Reserved.

For permission to reproduce any contents of this web site, please email our Syndication department: .

Full details for the use of materials on this site can be found in the Terms & Conditions.

Subscribe to Other Decision News Media E-newsletters - Pharmaceutical & Science Pharmaceutical Technology Drug Discovery Pharmaceutical Contract Services Biopharmaceutical Science and Business Laboratory Equipment Scientific Computing & Instrumentation Microscopy Spectroscopy Chromatography and Separations Sciences Packaging Technologies & Markets B2B Marketing Newsletter Confirm registration E-newsletters for food & beverage All Decision News Media sites Food & Beverage Development - Europe - Supplements & Nutrition - Europe - Food Processing & Packaging - Europe - Food Marketing and Retailing - Supplements & Nutrition - North America - Beverage Tech...

Read more...